Promis Neurosciences (PMN) Stock Price, News & Analysis

Company Overview

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Key Stats

• Today's Range: $0.43 to $0.49
• 50-Day Range: $0.45 to $0.65
• 52-Week Range: $0.43 to $2.37
• Volume: 171,284 shs
• Average Volume: 81,089 shs
• Market Capitalization: $15.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Buy

Promis Neurosciences Stock Analysis - MarketRank™

Promis Neurosciences scored higher than 68% of companies evaluated by MarketBeat, and ranked 808th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Promis Neurosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Promis Neurosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Promis Neurosciences are expected to grow in the coming year, from ($0.24) to ($0.21) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Promis Neurosciences is -9.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Promis Neurosciences is -9.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Promis Neurosciences has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.61% of the float of Promis Neurosciences has been sold short.

Short Interest Ratio / Days to Cover

Promis Neurosciences has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Promis Neurosciences has recently decreased by 15.83%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Promis Neurosciences does not currently pay a dividend.

Dividend Growth

Promis Neurosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.61% of the float of Promis Neurosciences has been sold short.

Short Interest Ratio / Days to Cover

Promis Neurosciences has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Promis Neurosciences has recently decreased by 15.83%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Promis Neurosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.11% of the stock of Promis Neurosciences is held by insiders.

Percentage Held by Institutions

50.13% of the stock of Promis Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PMN Stock Analysis - Frequently Asked Questions

How have PMN shares performed this year?

Promis Neurosciences' stock was trading at $0.9478 at the beginning of 2025. Since then, PMN shares have decreased by 51.2% and is now trading at $0.4630.

How were Promis Neurosciences' earnings last quarter?

Promis Neurosciences (NASDAQ:PMN) announced its earnings results on Monday, May, 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.07.

How do I buy shares of Promis Neurosciences?

Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Promis Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Promis Neurosciences investors own include PayPal (PYPL), Recursion Pharmaceuticals (RXRX), Pacific Biosciences of California (PACB), Editas Medicine (EDIT), Exscientia (EXAI) and Trimble (TRMB).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/04/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PMN
• CIK: 1374339
• Web: www.promisneurosciences.com
• Phone: (416) 847-6898
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.50
• High Stock Price Target: $6.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +871.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $2.78 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -186.19%
• Return on Assets: -98.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.36
• Quick Ratio: 3.36

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.50 per share
• Price / Book: 0.93

Miscellaneous

• Outstanding Shares: 32,690,000
• Free Float: 30,692,000
• Market Cap: $15.14 million
• Optionable: Not Optionable
• Beta: -0.10